Advancing Affordable Biologics
Advancing Affordable Biologics
Advancing Affordable Biologics
Biosimilar development and manufacturing costs are far too high for widespread access of these life-saving and/or life-comforting drugs.
Biosimilar development and manufacturing costs are far too high for widespread access of these life-saving and/or life-comforting drugs.
About Us
About Us
A next generation Biosimilar Company
A next generation Biosimilar Company
Recent advancements in Continuous Manufacturing (CM), artificial intelligence and machine learning (AI/ML) and anticipated regulatory shifts—such as the potential waiver of Phase III clinical trials—have paved the way for a new biosimilar development and manufacturing company. Ardent Biopharma is seizing this opportunity to redefine cost efficiency in the production of monoclonal antibodies (mAbs) and other therapeutic proteins.
Recent advancements in Continuous Manufacturing (CM), artificial intelligence and machine learning (AI/ML) and anticipated regulatory shifts—such as the potential waiver of Phase III clinical trials—have paved the way for a new biosimilar development and manufacturing company. Ardent Biopharma is seizing this opportunity to redefine cost efficiency in the production of monoclonal antibodies (mAbs) and other therapeutic proteins.
€100/gr
€100/gr
CoGs in 2030
€100/gr
€100/gr
CoGs in 2030
€100/gr
€100/gr
CoGs in 2030
2026
2026
First Market Authorization
2026
2026
First Market Authorization
2026
2026
First Market Authorization
€100M
€100M
Development Costs
€100M
€100M
Development Costs
€100M
€100M
Development Costs
Leveraging these innovations, we aim to deliver biosimilars below 20% of the originator price, significantly improving global affordability and accessibility to life-saving or life-enhancing biologic therapies. Ardent aspires to become a cost leader in the biosimilars industry. Both first and second wave biosimilars will be developed.
Development will be done in close collaboration with our partners until we can operate from a proprietary facility. Future product M&S will be realized through specialized parties per region.
Leveraging these innovations, we aim to deliver biosimilars below 20% of the originator price, significantly improving global affordability and accessibility to life-saving or life-enhancing biologic therapies. Ardent aspires to become a cost leader in the biosimilars industry. Both first and second wave biosimilars will be developed.
Development will be done in close collaboration with our partners until we can operate from a proprietary facility. Future product M&S will be realized through specialized parties per region.
Our products
Our products
Our pipeline
Our pipeline
Ardent is developing a pipeline of biosimilars that will be presented to the authorities without the execution of a Clinical Efficacy Study (phase III). The MHRA, FDA and EMA have already announced the willingness to waive a phase III trial for applications with thorough scientific evidence showing that all critical quality attributes fall within the variability of the reference product. Development costs will decline dramatically giving Ardent a first mover advantage.
Development and early-stage manufacturing will be outsourced to our CDMO partner and a diversity of contract labs. Upon market validation, production will transition to Ardent’s dedicated CM facility.
Ardent is developing a pipeline of biosimilars that will be presented to the authorities without the execution of a Clinical Efficacy Study (phase III). The MHRA, FDA and EMA have already announced the willingness to waive a phase III trial for applications with thorough scientific evidence showing that all critical quality attributes fall within the variability of the reference product. Development costs will decline dramatically giving Ardent a first mover advantage.
Development and early-stage manufacturing will be outsourced to our CDMO partner and a diversity of contract labs. Upon market validation, production will transition to Ardent’s dedicated CM facility.
Our Process
Our Process
Our competitive Edge
Our competitive Edge
Ardent’s competitive edge is built on a highly efficient and innovative approach to mAb biosimilar development and manufacturing.
Ardent’s competitive edge is built on a highly efficient and innovative approach to mAb biosimilar development and manufacturing.
01
Cost-efficient Continuous Manufacturing
utilizing high-productivity cell lines
01
Cost-efficient Continuous Manufacturing
utilizing high-productivity cell lines
01
Cost-efficient Continuous Manufacturing
utilizing high-productivity cell lines
02
Regulatory strategy
focused on biosimilar approval without the need for confirmatory efficacy studies.
02
Regulatory strategy
focused on biosimilar approval without the need for confirmatory efficacy studies.
02
Regulatory strategy
focused on biosimilar approval without the need for confirmatory efficacy studies.
03
Accelerated development timelines
with biosimilars brought to market in 5 years vs current timelines of 7-9 years.
03
Accelerated development timelines
with biosimilars brought to market in 5 years vs current timelines of 7-9 years.
03
Accelerated development timelines
with biosimilars brought to market in 5 years vs current timelines of 7-9 years.
04
Lean organization with highly experienced personnel
to minimize overhead and maximize agility.
04
Lean organization with highly experienced personnel
to minimize overhead and maximize agility.
04
Lean organization with highly experienced personnel
to minimize overhead and maximize agility.
Our Team
Our Team
Experienced In All The Required Disciplines
Experienced In All The Required Disciplines
Ardent Biopharma’s core team brings together over 100 years of combined experience in biologics development and manufacturing, with deep expertise in Continuous Manufacturing of mAbs. Our multidisciplinary team covers the full spectrum of product development – cell line development, process & analytical development, CMC, GMP manufacturing & compliance, quality assurance, clinical and regulatory affairs. Furthermore, Ardent can rely on an established network of high-level industry specialists.
Ardent Biopharma’s core team brings together over 100 years of combined experience in biologics development and manufacturing, with deep expertise in Continuous Manufacturing of mAbs. Our multidisciplinary team covers the full spectrum of product development – cell line development, process & analytical development, CMC, GMP manufacturing & compliance, quality assurance, clinical and regulatory affairs. Furthermore, Ardent can rely on an established network of high-level industry specialists.
Partnership
Partnership
Collaborations
Collaborations
Ardent Biopharma collaborates closely with simAbs (Belgian CDMO), forming a synergistic partnership with strong capabilities in mAb development and continuous manufacturing. This alliance is strategically positioned to develop low COGs biosimilars with long term stability and robust structural & functional comparability data.
We actively seek partnerships that share our mission of reducing the costs of mAb manufacturing and development timelines.
Ardent Biopharma collaborates closely with simAbs (Belgian CDMO), forming a synergistic partnership with strong capabilities in mAb development and continuous manufacturing. This alliance is strategically positioned to develop low COGs biosimilars with long term stability and robust structural & functional comparability data.
We actively seek partnerships that share our mission of reducing the costs of mAb manufacturing and development timelines.
Ardent Biopharma collaborates closely with simAbs (Belgian CDMO), forming a synergistic partnership with strong capabilities in mAb development and continuous manufacturing. This alliance is strategically positioned to develop low COGs biosimilars with long term stability and robust structural & functional comparability data.
We actively seek partnerships that share our mission of reducing the costs of mAb manufacturing and development timelines.
News & Insights
News & Insights
